Preclinical Evaluation of Lipid-Based Nanosystems
Silva, Ana Catarina
Preclinical Evaluation of Lipid-Based Nanosystems - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021 - 1 electronic resource (351 p.)
Open Access
The use of lipid-based nanosystems, including lipid nanoparticles (solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)), nanoemulsions, and liposomes, among others, is widespread. Several researchers have described the advantages of different applications of these nanosystems. For instance, they can increase the targeting and bioavailability of drugs, improving therapeutic effects. Their use in the cosmetic field is also promising, owing to their moisturizing properties and ability to protect labile cosmetic actives. Thus, it is surprising that only a few lipid-based nanosystems have reached the market. This can be explained by the strict regulatory requirements of medicines and the occurrence of unexpected in vivo failure, which highlights the need to conduct more preclinical studies.Current research is focused on testing the in vitro, ex vivo, and in vivo efficacy of lipid-based nanosystems to predict their clinical performance. However, there is a lack of method validation, which compromises the comparison between different studies.This book brings together the latest research and reviews that report on in vitro, ex vivo, and in vivo preclinical studies using lipid-based nanosystems. Readers can find up-to-date information on the most common experiments performed to predict the clinical behavior of lipid-based nanosystems. A series of 15 research articles and a review are presented, with authors from 15 different countries, which demonstrates the universality of the investigations that have been carried out in this area.
Creative Commons
English
books978-3-0365-1549-6 9783036515502 9783036515496
10.3390/books978-3-0365-1549-6 doi
Technology: general issues
nanostructured lipid carriers (NLC) formulation optimization rivastigmine quality by design (QbD) nasal route nose-to-brain N-alkylisatin liposome urokinase plasminogen activator PAI-2 SerpinB2 breast cancer liposomes target delivery nanosystem FZD10 protein colon cancer therapy supersaturation silica-lipid hybrid spray drying lipolysis lipid-based formulation fenofibrate mesoporous silica oral drug delivery hyaluronic acid drug release light activation stability mobility biocorona dissolution enhancement phospholipids solid dosage forms porous microparticles nanoemulsion(s) phase-behavior DoE D-optimal design vegetable oils non-ionic surfactants efavirenz flaxseed oil nanostructured lipid carriers nanocarrier docohexaenoic acid neuroprotection neuroinflammation fluconazole Box‒Behnken design nanotransfersome ulcer index zone of inhibition rheological behavior ex vivo permeation nanomedicine cancer doxorubicin melanoma drug delivery ultrasound contrast agents phospholipid coating ligand distribution cholesterol acoustic response microbubble lipid phase dialysis ammonia intoxication cyanocobalamin vitamin B12 atopic dermatitis psoriasis transferosomes lipid vesicles skin topical delivery oligonucleotide self-emulsifying drug delivery systems hydrophobic ion pairing intestinal permeation enhancers Caco-2 monolayer clarithromycin solid lipid nanoparticles optimization permeation pharmacokinetics follicular targeting dexamethasone alopecia areata lipomers lipid polymer hybrid nanocapsules biodistribution skin ethyl cellulose n/a
Preclinical Evaluation of Lipid-Based Nanosystems - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021 - 1 electronic resource (351 p.)
Open Access
The use of lipid-based nanosystems, including lipid nanoparticles (solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)), nanoemulsions, and liposomes, among others, is widespread. Several researchers have described the advantages of different applications of these nanosystems. For instance, they can increase the targeting and bioavailability of drugs, improving therapeutic effects. Their use in the cosmetic field is also promising, owing to their moisturizing properties and ability to protect labile cosmetic actives. Thus, it is surprising that only a few lipid-based nanosystems have reached the market. This can be explained by the strict regulatory requirements of medicines and the occurrence of unexpected in vivo failure, which highlights the need to conduct more preclinical studies.Current research is focused on testing the in vitro, ex vivo, and in vivo efficacy of lipid-based nanosystems to predict their clinical performance. However, there is a lack of method validation, which compromises the comparison between different studies.This book brings together the latest research and reviews that report on in vitro, ex vivo, and in vivo preclinical studies using lipid-based nanosystems. Readers can find up-to-date information on the most common experiments performed to predict the clinical behavior of lipid-based nanosystems. A series of 15 research articles and a review are presented, with authors from 15 different countries, which demonstrates the universality of the investigations that have been carried out in this area.
Creative Commons
English
books978-3-0365-1549-6 9783036515502 9783036515496
10.3390/books978-3-0365-1549-6 doi
Technology: general issues
nanostructured lipid carriers (NLC) formulation optimization rivastigmine quality by design (QbD) nasal route nose-to-brain N-alkylisatin liposome urokinase plasminogen activator PAI-2 SerpinB2 breast cancer liposomes target delivery nanosystem FZD10 protein colon cancer therapy supersaturation silica-lipid hybrid spray drying lipolysis lipid-based formulation fenofibrate mesoporous silica oral drug delivery hyaluronic acid drug release light activation stability mobility biocorona dissolution enhancement phospholipids solid dosage forms porous microparticles nanoemulsion(s) phase-behavior DoE D-optimal design vegetable oils non-ionic surfactants efavirenz flaxseed oil nanostructured lipid carriers nanocarrier docohexaenoic acid neuroprotection neuroinflammation fluconazole Box‒Behnken design nanotransfersome ulcer index zone of inhibition rheological behavior ex vivo permeation nanomedicine cancer doxorubicin melanoma drug delivery ultrasound contrast agents phospholipid coating ligand distribution cholesterol acoustic response microbubble lipid phase dialysis ammonia intoxication cyanocobalamin vitamin B12 atopic dermatitis psoriasis transferosomes lipid vesicles skin topical delivery oligonucleotide self-emulsifying drug delivery systems hydrophobic ion pairing intestinal permeation enhancers Caco-2 monolayer clarithromycin solid lipid nanoparticles optimization permeation pharmacokinetics follicular targeting dexamethasone alopecia areata lipomers lipid polymer hybrid nanocapsules biodistribution skin ethyl cellulose n/a